"FDA DEFENSE" NOT IN BIPARTISAN SENATE PRODUCT LIABILITY BILL INTRODUCED MARCH 15; GORTON/ROCKEFELLER's S 565 MEASURE WOULD CAP ALL PUNITIVE DAMAGE AWARDS
The Senate Commerce Committee leadership is pushing an unadorned version of product liability legislation that focuses on a cap on punitive damage awards and does not contain special provisions for classes of products such as drugs and medical devices. A bill with bipartisan sponsorship (S 565) introduced on March 15 does not include the "FDA defense" adopted in the House bill (HR 956).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth